These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9193349)

  • 1. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; Oosterwijk-Wakka JC; Oosterhof GO; Witjes JA; Koenders EB; Oyen WJ; Buijs WC; Debruyne FM; Corstens FH; Oosterwijk E
    J Clin Oncol; 1997 Apr; 15(4):1529-37. PubMed ID: 9193349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
    Steffens MG; Boerman OC; Oyen WJ; Kniest PH; Witjes JA; Oosterhof GO; van Leenders GJ; Debruyne FM; Corstens FH; Oosterwijk E
    Cancer Res; 1999 Apr; 59(7):1615-9. PubMed ID: 10197637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
    Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
    J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
    Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.
    Oosterwijk E; Bander NH; Divgi CR; Welt S; Wakka JC; Finn RD; Carswell EA; Larson SM; Warnaar SO; Fleuren GJ
    J Clin Oncol; 1993 Apr; 11(4):738-50. PubMed ID: 8478666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
    Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
    Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
    Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
    Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
    Divgi CR; O'Donoghue JA; Welt S; O'Neel J; Finn R; Motzer RJ; Jungbluth A; Hoffman E; Ritter G; Larson SM; Old LJ
    J Nucl Med; 2004 Aug; 45(8):1412-21. PubMed ID: 15299069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
    Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
    Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
    Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
    J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.
    Oosterwijk E; Debruyne FM
    World J Urol; 1995; 13(3):186-90. PubMed ID: 7550393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas.
    Steffens MG; Oosterwijk E; Zegwaart-Hagemeier NE; van't Hof MA; Debruyne FM; Corstens FH; Boerman OC
    Br J Cancer; 1998 Nov; 78(9):1208-13. PubMed ID: 9820182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
    Brouwers AH; Dorr U; Lang O; Boerman OC; Oyen WJ; Steffens MG; Oosterwijk E; Mergenthaler HG; Bihl H; Corstens FH
    Nucl Med Commun; 2002 Mar; 23(3):229-36. PubMed ID: 11891480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.